Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


11 Items
Title  Creator  Group name  Publishing year 
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival Chauvin et al. EquipeCG 2021-07
Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells Chauvin et al. EquipeCTCS 2021-01-26
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest Pichard et al. EquipeNB May 2020
Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept Rondon et al. EquipeJPP 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Ashraf et al. EquipeAT Feb 04, 2019
Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and non-targeted response to alpha and Auger radioimmunotherapy Ladjohounlou et al. PlateformeIPAM May 06, 2019
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer Deshayes et al. PlateformeIPAM Aug 2018
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages Bougherara et al. PlateformePP2I Nov 21, 2017
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells Estupina et al. PlateformePP2I Jun 06, 2017
Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects Paillas et al. EquipeELC 09 10, 2016
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4 Kersual et al. EquipeCG 2014
11 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés